The following Listing of the Claims will replace all prior versions and all prior listings of the claims in the present application:

Listing of The Claims:

1. (Currently Amended) A method of stimulating an immune response to an antigen, the method comprising

administering to a mammal a composition comprising a cell that provides said antigen and has an engineered cytokine bound to the cell surface, said composition being substantially free of cells that have been genetically modified to produce cytokine, said engineered cytokine including ~~comprising said antigen admixed with~~

~~an engineered cytokine,~~

~~wherein said engineered cytokine is bound to said cell, and wherein said engineered cytokine~~ ~~comprises~~ (1) first portion from a cytokine, and (2) a second portion ~~moiety~~ heterologous to said cytokine, said second portion being capable of binding to ~~wherein said moiety binds to~~ said cell when said engineered cytokine is mixed with said cell exogenously, and wherein an immune response is stimulated in said mammal to said antigen following administration of said composition.

2. (Currently Amended) A method of stimulating an immune response to an antigen, the method comprising

producing a composition by admixing a cell comprising said antigen with a cytokine which is exogenous to said cell and which binds to said cell ~~producing a cytokine-coated cell,~~ wherein said cytokine-coated cell has not been genetically modified to produce cytokine; and

administering to a mammal said ~~cytokine-coated cell~~ composition, wherein an immune response is stimulated in said mammal to said antigen.

3. (Previously Presented) The method of claim 1 or claim 2 wherein said composition further comprises an opsonin-enhanced cell.

4. (Previously Presented) The method of claim 3 wherein said opsonin of said opsonin-enhanced cell is selected from the group consisting of mannose binding protein or the alpha' chain of C3b.

5. (Currently Amended) The method of ~~any one of~~ claims 1 ~~or 2~~ wherein said second portion ~~cytokine of said cytokine-coated cell~~ comprises a lipid.

6. (Currently Amended) The method of claim 5 wherein said ~~cytokine~~ second portion comprises a GPI moiety.

7. (Currently Amended) The method of claim 5 wherein said ~~cytokine~~ second portion comprises a fatty acid.

8. (Previously Presented) The method of claim 7 wherein said fatty acid is palmitate.

9-12. (Cancelled)

13. (Currently Amended) A method of stimulating an immune response to an antigen, the method comprising

administering to a mammal a composition comprising a cell said composition including a cell that provides said antigen and has an engineered cytokine bound to the cell surface, said composition being substantially free of cells that have been genetically modified to produce cytokine,

said engineered cytokine including: ~~comprising said antigen admixed with~~

~~an engineered cytokine~~

~~wherein said engineered cytokine is bound to said cell, and wherein said engineered cytokine comprises~~ (1) a first portion from a cytokine which is a ligand for the GM-CSF receptor, and (2) a ~~moiety~~ second portion heterologous to said cytokine, said second portion being capable of binding to ~~wherein said moiety binds to~~ said cell when said engineered

cytokine is mixed with said cell exogenously, and wherein an immune response is stimulated in said mammal to said antigen following administration of said composition.

14. (Original) The method of claim 13, wherein said ligand for the GM-CSF receptor is GM-CSF.

15. (Cancelled)

16. (Cancelled)

17. (Currently Amended) The method of any one of claims 1 or 13, wherein said cell ~~of said cytokine-coated cell~~ is a pathogenic cell.

18. (Original) The method of claim 17 wherein said pathogenic cell is a malignant tumor cell.

19. (Previously Presented) The method of claim 17 wherein said cell of said pathogenic cell is selected from the group consisting of: a bacterium, a virus, a fungus, and a cell of a parasite.

20. (Previously Presented) The method of claim 17, wherein said composition further comprises an opsonin-enhanced pathogenic cell.

21. (Cancelled)

22. (Currently Amended) The method of any one of claims 1 or 13 wherein said ~~cytokine-coated~~ cell is substantially unable to divide in vitro.

23. (Currently Amended) The method of any one of claims 1 or 13, wherein said ~~cytokine-coated~~ cell is attenuated.

24. (Previously Presented) The method of any one of claims 1 or 13, wherein said cytokine is an antitumor cytokine.

25. (Previously Presented) The method of any one of claims 1 or 13, wherein said cytokine is extremely bioactive, natively bioactive, or suprabioactive.

26. (New) The method of claim 1 or 2 wherein said cell is also an opsonin enhanced cell.